Straits Times Index
3,246.51 -26.97 (-0.82%) Nikkei
28,930.33 -11.81 (-0.04%) Hang Seng
19,773.03 +9.12 (+0.05%) FTSE 100
7,550.37 +8.52 (+0.11%) BTC-USD
21,022.26 -1,960.58 (-8.53%) CMC Crypto 200
504.88 -36.72 (-6.78%)
CHRS Aug 2022 15.000 call
| Previous close | 0.2000 |
| Open | 0.2500 |
| Bid | 0.0000 |
| Ask | 4.8000 |
| Strike | 15.00 |
| Expiry date | 2022-08-19 |
| Day's range | 0.2000 - 0.2500 |
| Contract range | N/A |
| Volume | |
| Open interest | 105 |
- Zacks
Wall Street Analysts Think Coherus BioSciences (CHRS) Could Surge 47%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 47.3% in Coherus BioSciences (CHRS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- Motley Fool
Coherus BioSciences (CHRS) Q2 2022 Earnings Call Transcript
This release can be found on the Coherus BioSciences website and is also attached to our Form 8-K. Today's call includes forward-looking statements regarding Coherus' current expectations about future events. All these forward-looking statements involve substantial risks and uncertainties that are beyond our control and could cause actual results, performance or achievements to differ from results, performance or achievements implied by the forward-looking statements.
- Zacks
Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 32.29% and 3.71%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
